Orakl Closes 30 Million Euro Series A for Tumor Models

Orakl Oncology’s co-lead investor Norrsken announced a new €30 million ($34 million) Series A on November 12, with Singular as co-lead. The financing supports patient-derived tumor biology and AI models to predict oncology drug…




